Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Sayers Website

Thomas J. Sayers, Ph.D.

Selected Publications

1)  Sayers K, Brooks A, Sayers T, Chertov O.
Increased Secretory Leukocyte Protease Inhibitor (SLPI) Production by Highly Metastatic Mouse Breast Cancer Cells.
PLOS One. 2014.
In Press. [Journal]
2)  Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.
Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/aCD40 Therapy.
J. Immunol. [Epub ahead of print], 2014.
3)  Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M.
A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells.
J Biomol Screen. 17: 1231-42, 2012.
4)  Henrich CJ, Thomas CL, Brooks AD, Booth NL, Lowery EM, Pompei RJ, McMahon JB, Sayers TJ.
Effects of cucurbitacins on cell morphology are associated with sensitization of renal carcinoma cells to TRAIL-induced apoptosis.
Apoptosis. 17: 79-89, 2012.
5)  Malyguine AM, Strobl S, Dunham K, Shurin MR, Sayers TJ.
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials.
Cells. 1: 111-26, 2012.
6)  Whitson EL, Sun H, Thomas CL, Henrich CJ, Sayers TJ, McMahon JB, Griesinger C, McKee TC.
Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.
J. Nat. Prod. 75: 394-9, 2012.
7)  Sayers TJ.
Targeting the extrinsic apoptosis signaling pathway for cancer therapy.
Cancer Immunol. Immunother. 60: 1173-80, 2011.
8)  Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H.
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.
Mol. Cancer Ther. 9: 1842-51, 2010.
9)  Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ.
Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Mol. Cancer Res. 8: 729-38, 2010.
10)  de Kluyver RL, Sayers TJ.
Breast cancer bone metastases: Combination therapy targeting cancer cells and the tumor microenvironment.
Cancer Biol Ther. 9: 551-3, 2010.
11)  Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM.
New flow cytometric assays for monitoring cell-mediated cytotoxicity.
Expert Rev Vaccines. 9: 601-16, 2010.
12)  Lee S, Yagita H, Sayers TJ, Celis E.
Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
Cancer Immunol. Immunother. 59: 1073-81, 2010.
13)  Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan S, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP.
Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.
Blood. 116: 4192-201, 2010.
14)  Shanker A, Brooks AD, Jacobsen KM, Wine JW, Wiltrout RH, Yagita H, Sayers TJ.
Antigen Presented by Tumors In vivo Determines the Nature of CD8+ T-Cell Cytotoxicity.
Cancer Res. 69: 6615-23, 2009.
15)  Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, Dai RM, Scheetz L, Lincoln E, Back TC, Powell D, Hurwitz AA, Sayers TJ, Kastelein R, Pavlakis GN, Felber BK, Trinchieri G, Wigginton JM.
Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
J. Immunol. 182: 4328-38, 2009.
16)  Booth NL, Sayers TJ, Brooks AD, Thomas CL, Jacobsen K, Goncharova EI, McMahon JB, Henrich CJ.
A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.
Cancer Immunol. Immunother. 58: 1229-44, 2008.
17)  Sayers T.
Productively combining proteasome inhibition with the immunotherapy of cancer.
J. Mol. Med. 86: 857-60, 2008.
18)  Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.
J. Natl. Cancer Inst. 100: 649-62, 2008.
19)  Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ.
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP.
Blood. 102: 303-10, 2003.
20)  Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ, Sayers TJ.
Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer.
Cancer Res. 63: 207-13, 2003.
21)  Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ.
Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
J. Immunol. 168: 3484-92, 2002.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/4/2014.